JTE522 is primarily utilized in the field of medical research and pharmacology, particularly in the study and development of treatments for gastrointestinal disorders. It functions as a potent and selective prostaglandin EP4 receptor antagonist, which plays a significant role in modulating inflammation and pain pathways. Researchers employ JTE522 to investigate its potential in alleviating conditions such as inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, by targeting the EP4 receptor to reduce inflammation. Additionally, its application extends to cancer research, where it is studied for its potential to inhibit tumor growth and metastasis, as prostaglandin EP4 receptors are implicated in cancer progression. The compound's ability to selectively block these receptors makes it a valuable tool in understanding and developing targeted therapies for various inflammatory and oncological conditions.